The treatment of lower respiratory tract infections will undoubtedly be affected by cost-control measures. Probably the most important change in the diagnosis and treatment of bronchitis and pneumonia will be a more empiric approach. A basic knowledge of likely pathogens, plus the clinical judgment to provide treatment modifications for patients susceptible to unusual pathogens, will usually assure a successful outcome.